Senior Director, Nonclinical Safety Evaluation

*
* The Role:

** At Moderna, our mission is to deliver the greatest possible impact to people through mRNA medicines. We foster a dynamic, diverse, and innovative workplace where every individual’s contribution is vital.

We are seeking a seasoned scientific leader to serve in a senior leadership role within Nonclinical Safety Evaluation, providing strategic and operational leadership for Toxicology and Pathology. This role will serve on a leadership team with other nonclinical leaders and will partner closely with other cross-functional stakeholders to ensure scientifically rigorous, acceptable, and compliant nonclinical safety strategies and data packages to support regulatory submissions.

This role will have specific emphasis and accountability for products in Moderna’s emerging and/or established Systemic IV portfolio (spanning Autoimmune, Immuno-Oncology, and/or Rare Disease), with additional responsibilities to partner with Platform Science teams to support the safety evaluation and optimization of novel and existing technologies, as well as in other therapeutic areas as needed based on evolving business needs.
** Here’s What You’ll Do
*** In alignment with the corporate mindsets, provide direct and matrix management of a high performing team of Toxicologists and Pathologists across a range of job levels, cultivating a culture of innovation, collaboration, excellence, and continuous learning.
* Provide integrated strategic leadership for Toxicology and Pathology in support of nonclinical safety evaluation of products within the assigned therapeutic area(s) from discovery to post-marketing.
* Apply in-depth knowledge of how nonclinical safety disciplines (including but not limited to general toxicology, safety pharmacology, genotoxicity, developmental and reproductive toxicology, and carcinogenicity) integrate with other areas across the business.
* Evaluate non-clinical safety challenges in a complex or fast-changing environment and direct the development of new or innovative solutions with in-depth analysis and interpretive thinking.
* Provide strategic oversight on and coach/guide team members on the development of scientifically-sound nonclinical safety strategies to provide expert support to discovery and development projects.
* Accountable for the design, execution, critical analysis, and reporting of GLP/non-GLP nonclinical safety in vitro and/or in vivo studies conducted in multiple species under the nonclinical safety assessment umbrella for the assigned therapeutic area(s) via collaborative partnerships with study monitors and program team representatives (e.g., DMPK, bioanalytical, operations, etc.).
* May be accountable for toxicology assessments supporting extractable/leachable and contaminant risk assessments and/or impurity qualification.
* Serve as a key scientific contributor in regulatory agency interactions, internal governance and/or leadership meetings when nonclinical data package conclusions and impact of GLP/non-GLP study results on program and clinical/regulatory strategy are presented.
* Apply expert scientific and regulatory writing experience when critically reviewing, editing, and authoring submission application documents (INDs, CTAs, BLAs and MAAs) and health authority interaction documents (e.g., briefing documents, regulatory query responses), ensuring effective integration of toxicology results with DMPK and pharmacology for the assigned therapeutic area(s). Ensure alignment of toxicology narratives with clinical development plans and regulatory strategies.
* Oversee the preparation and presentation of nonclinical safety data for project teams, portfolio management, internal/external partners and/or scientific groups in a concise and meaningful way.
* Maintain extensive scientific awareness and presence internally and externally, leading initiatives to publish manuscripts and posters, present at scientific conferences and other scientific forums, engage with consultants and advisors in the field, as well as the scientific community at large.
* In addition to providing direct and matrix management, the incumbent will also serve as an independent contributor for a…